Actelion Launches 500-Patient Phase III Trial For Next-Generation PAH Drug

Taking the Actelion-1 compound to market would give Swiss firm an edge in PAH battle with Gilead.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet